Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20911434 | 1.00 | GLP1R (0.56) | GLP1RNOD1FOLH1EPHX2GNPAT | |
| SCHEMBL29322234 | 0.94 | GLP1R (0.52) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL16273259 | 0.93 | NOD1 (0.59) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL20910955 | 0.92 | EPHX2 (0.50) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL20910956 | 0.92 | EPHX2 (0.50) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL24173323 | 0.90 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL24173761 | 0.90 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL23157321 | 0.90 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL23157341 | 0.90 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL24174150 | 0.90 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885FOLH1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.